TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01403129

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography (OCT) Exam
Description: OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
Study: NCT03811158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC
Description: Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: UHFOM
Description: Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
Study: NCT01276197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Story-Telling DVD
Description: DVD will contain both informational and story-telling components.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Storytelling DVD
Description: DVD will contain only informational component.
Study: NCT02086773

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Study: NCT04427657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous microfragmented lipoaspirate tissue (Lipogems®).
Description: patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic debridment
Description: patient in supine position. Under sedation is perform an arthroscopic debridement
Study: NCT04550507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful sensory awareness intervention
Description: The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
Study: NCT01860638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC Agent
Description: The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
Study: NCT00932477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
Description: 1 to 2 drops into each eye three times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
Description: 1 to 2 drops into each eye three times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin and Polysorbate 80 based artificial tear
Description: 1 to 2 drops into each eye three times per day
Study: NCT03629054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl
Description: single dose
Study: NCT02331563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: ultrasound guided transvers abdominis plane block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 % bupivacaine
Description: ultrasound guided transvers abdominis plane block
Study: NCT01522820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given intranodally
Study: NCT03279068

Intervention type: OTHER
Intervention: Teaching and EFM Paper
Description: Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
Study: NCT03254368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-1061
Description: ZGN-1061 is a methionine aminopeptidase 2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-1061
Description: ZGN-1061 is a methionine aminopeptidase 2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-1061
Description: ZGN-1061 is a methionine aminopeptidase 2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-1061
Description: ZGN-1061 is a methionine aminopeptidase 2 inhibitor
Study: NCT04701983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab SAR440340
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab SAR440340
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Study: NCT03254368

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo has the same excipients and appearance as ZGN-1061
Study: NCT00454831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEP-40 chitosan
Description: Enzymatically Hydrolyzed Polychitosamine-40 kDa

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEP-40 chitosan
Description: Enzymatically Hydrolyzed Polychitosamine-40 kDa

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEP-40 chitosan
Description: Enzymatically Hydrolyzed Polychitosamine-40 kDa

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEP-40 chitosan
Description: Enzymatically Hydrolyzed Polychitosamine-40 kDa

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HEP-40 chitosan
Description: Enzymatically Hydrolyzed Polychitosamine-40 kDa
Study: NCT01275339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
Study: NCT02607644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Description: Laryngeal Mask Airway (LMA) for Control group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Description: Laryngeal Tube (LT) for Intervention group
Study: NCT02387255

Intervention type: DEVICE
Intervention: Resoundant Driver System
Description: This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.

Intervention type: DEVICE
Intervention: Resoundant Driver System
Description: This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.

Intervention type: DEVICE
Intervention: Resoundant Driver System
Description: This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
Study: NCT04139200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 1 physical activity tele coaching intervention
Description: A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Type 2 physical activity tele coaching intervention
Description: A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
Study: NCT01511666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS
Description: ECLS states for extracorporeal life support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care as per recent guidelines will be provided.
Study: NCT01221454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic bone marrow stem cells transplantation
Description: 30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved therapy
Description: Oral or intravenous administration
Study: NCT01362595

Intervention type: DRUG
Group type: OTHER
Intervention: leucine
Description: Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day
Study: NCT01251627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
Study: NCT02153476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg of ALG-1001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution
Study: NCT00921245

Intervention type: DRUG
Intervention: Darifenacin (Emselex, BAY79-4998)
Description: Patients in daily clinical treatment receiving Emselex according to local drug information
Study: NCT03818984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer Conception for Men with At Risk Partners
Description: CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
Study: NCT02044497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral oxycodone
Study: NCT01931670

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Study: NCT01840839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Study: NCT01541345

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone graft
Description: Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: InductOs
Description: CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmentation surgery
Description: CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
Study: NCT01988480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided surgery
Description: Placement on residual bone around the implant

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sinus lift surgery
Description: Allograft bone
Study: NCT03686644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wearing of night splint ankle foot orthoses (phase A)
Description: Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No wearing of night splint ankle foot orthoses (phase B)
Description: Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results.
Study: NCT00859261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental 3D Breast Ultrasound imaging
Description: Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Photoacoustic Imaging
Description: Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
Study: NCT01736657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red blood cell exchange in sickle cell
Description: One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
Study: NCT02597816

Intervention type: RADIATION
Group type: OTHER
Intervention: Three dimensional ultrasound
Study: NCT02326311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: Tyrosin kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: Tyrosin kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nilotinib
Description: Tyrosin kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Tyrosin kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib
Description: Tyrosin kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tyrosin kinase inhibitor
Study: NCT02876640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoid 9cUAB30
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo tumor resection surgery
Study: NCT00946400

Intervention type: OTHER
Intervention: Scoring 4Ts and Chong scale
Description: Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.

Intervention type: OTHER
Intervention: Blood draw
Description: Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
Study: NCT05715879

Intervention type: DIAGNOSTIC_TEST
Intervention: covid infection
Description: patients with covid infection which was proved with positive test

Intervention type: BIOLOGICAL
Intervention: admission to hispital
Description: patients with sever covid disease, who was admitted in hospital
Study: NCT03989726

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation
Description: AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
Study: NCT04062318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online active TMS
Description: One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online active TMS
Description: One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold.